Skip to main content

Table 2 Response and drug survival rate in AS patients treated with TNF-α blocking therapy

From: Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study

  Total IFX ETA ADA
Number of patients 220 32 137 51
ASAS20 responders at three months 68% 80% 66% 65%
(number of patients) (145 of 214) (24 of 30) (88 of 133) (33 of 51)
ASAS20 responders at six months 63% 71% 66% 51%
(number of patients) (132 of 209) (22 of 31) (86 of 131) (24 of 47)
ASAS40 responders at three months 49% 63% 47% 45%
(number of patients) (104 of 214) (19 of 30) (62 of 133) (23 of 51)
ASAS40 responders at six months 46% 52% 48% 38%
(number of patients) (97 of 209) (16 of 31) (63 of 131) (18 of 47)
BASDAI50 responders at three months 49% 60% 46% 51%
(number of patients) (105 of 214) (18 of 30) (61 of 133) (26 of 51)
BASDAI50 responders at six months 50% 48% 51% 47%
(number of patients) (104 of 209) (15 of 31) (67 of 131) (22 of 47)
One-year drug survival 71% 76% 72% 65%
(number of patients) (136 of 192) (22 of 29) (88 of 123) (26 of 40)
Two-year drug survival 66% 70% 69% 48%
(number of patients) (97 of 148) (19 of 27) (66 of 96) (12 of 25)
  1. See Table 1 for definitions.
  2. No statistical differences were found between treatment groups (P ≥0.05).
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us